What is HC Wainwright’s Estimate for ETON Q1 Earnings?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research note issued on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.05 for the quarter, down from their previous forecast of $0.09. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.37 EPS, FY2026 earnings at $0.81 EPS and FY2027 earnings at $1.25 EPS.

Separately, Craig Hallum raised their price target on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Price Performance

ETON opened at $12.45 on Wednesday. The business has a 50 day simple moving average of $8.10 and a 200-day simple moving average of $5.30. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $12.54.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ETON. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eton Pharmaceuticals during the third quarter worth $54,000. Jane Street Group LLC purchased a new position in Eton Pharmaceuticals during the third quarter worth $90,000. Renaissance Technologies LLC increased its position in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in Eton Pharmaceuticals during the second quarter worth $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares in the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Opaleye Management Inc. acquired 16,852 shares of Eton Pharmaceuticals stock in a transaction that occurred on Friday, October 4th. The stock was purchased at an average cost of $6.77 per share, with a total value of $114,088.04. Following the completion of the acquisition, the insider now owns 2,720,000 shares in the company, valued at $18,414,400. This trade represents a 0.62 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders bought 85,600 shares of company stock valued at $462,674. 14.89% of the stock is owned by insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.